Nathan Herrmann

4.4k total citations · 1 hit paper
62 papers, 3.2k citations indexed

About

Nathan Herrmann is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Nathan Herrmann has authored 62 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 23 papers in Psychiatry and Mental health and 9 papers in Physiology. Recurrent topics in Nathan Herrmann's work include Cholinesterase and Neurodegenerative Diseases (17 papers), Treatment of Major Depression (17 papers) and Dementia and Cognitive Impairment Research (15 papers). Nathan Herrmann is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (17 papers), Treatment of Major Depression (17 papers) and Dementia and Cognitive Impairment Research (15 papers). Nathan Herrmann collaborates with scholars based in Canada, United States and United Kingdom. Nathan Herrmann's co-authors include Krista L. Lanctôt, Claudio A. Naranjo, Paolo Mazzotta, Usoa E. Busto, Kenneth I. Shulman, Scott E. Walker, Sandra E. Black, Mario Masellis, Chris Heyn and Ying Meng and has published in prestigious journals such as Nature Communications, PLoS ONE and Biological Psychiatry.

In The Last Decade

Nathan Herrmann

61 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound

2018 666 citations Mario Masellis, Nathan Herrmann et al. profile →

Peers

Countries citing papers authored by Nathan Herrmann

Since Specialization

Citations

This map shows the geographic impact of Nathan Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Herrmann more than expected).

Fields of papers citing papers by Nathan Herrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Herrmann. The network helps show where Nathan Herrmann may publish in the future.

Co-authorship network of co-authors of Nathan Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Herrmann. A scholar is included among the top collaborators of Nathan Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Herrmann. Nathan Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Transcranial Direct Current Stimulation–Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial 2025 ·Biological Psychiatry ·(unknown), Heather Brooks, Clement Ma, Alina Lee, Marom Bikson, Aristotle N. Voineskos, Daniel M. Blumberger, Corinne E. Fischer, Alastair J. Flint, Nathan Herrmann, Sanjeev Kumar, Krista L. Lanctôt, Linda Mah, Benoit H. Mulsant, Bruce G. Pollock, Tarek K. Rajji	1
2	Exploring mitochondrial blood-based and genetic markers in older adults with mild cognitive impairment and remitted major depressive disorder 2024 ·Translational Psychiatry ·(unknown), Erika L. Beroncal, (unknown), Heather Brooks, James L. Kennedy, Carl Erik Fisher, Alastair J. Flint, Nathan Herrmann, Krista L. Lanctôt, Linda Mah, Benoit H. Mulsant, Bruce G. Pollock, Tarek K. Rajji, Ana C. Andreazza, (unknown)	2
3	Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis 2021 ·Brain Behavior and Immunity ·(unknown), (unknown), Brian Chan, Che‐Yuan Wu, (unknown), (unknown), Michelle Nguyen, Maureen Pakosh, Nathan Herrmann, Krista L. Lanctôt, Walter Swardfager	47
4	Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia 2019 ·Drugs & Aging ·(unknown), (unknown), (unknown), Krista L. Lanctôt, Nathan Herrmann	18
5	Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study 2018 ·PLoS ONE ·Paula A. Rochon, Andrea Gruneir, Chaim M. Bell, Rachel Savage, Sudeep S. Gill, Wei Wu, Vasily Giannakeas, Nathan M. Stall, Dallas Seitz, Sharon‐Lise T. Normand, Lynn Zhu, Nathan Herrmann, Lisa McCarthy, (unknown), Jerry H. Gurwitz, Peter C. Austin, Susan E. Bronskill	21
6	Therapeutic trial design for frontotemporal dementia and related disorders 2018 ·Journal of Neurology Neurosurgery & Psychiatry ·Philippe Desmarais, Jonathan D. Rohrer, Quôc Dinh Nguyên, Nathan Herrmann, Donald T. Stuss, Anthony E. Lang, Adam L. Boxer, Bradford C. Dickerson, Howie Rosen, John C. van Swieten, Lieke Meeter, Barbara Borroni, Maria Carmela Tartaglia, Howard Feldman, Sandra E. Black, Mario Masellis	12
7	Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation 2017 ·Expert Opinion on Drug Safety ·Dana Mohammad, (unknown), (unknown), Krista L. Lanctôt, Nathan Herrmann	58
8	Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments 2016 ·Current Alzheimer Research ·Celina S. Liu, Myuri Ruthirakuhan, Sarah Chau, Nathan Herrmann, André F. Carvalho, Krista L. Lanctôt	20
9	Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression 2013 ·CNS Drugs ·Kenneth I. Shulman, Nathan Herrmann, Scott E. Walker	171
10	Transdermal Rivastigmine 2011 ·CNS Drugs ·(unknown), Nathan Herrmann, David N. Adam	20
11	Persistence with Cholinesterase Inhibitor Therapy for Dementia 2009 ·Drugs & Aging ·Nathan Herrmann, Carin Binder, William Dalziel, (unknown), Fernando Camacho	35
12	Published randomized controlled trials of drug therapy for dementia often lack complete data on harm 2008 ·Journal of Clinical Epidemiology ·(unknown), Hadas D. Fischer, Paula A. Rochon, Sudeep S. Gill, Nathan Herrmann, Chaim M. Bell, K.V. Sýkora, G. M. Anderson	22
13	Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis 2008 ·Canadian Medical Association Journal ·Elmira Valiyeva, Nathan Herrmann, Paula A. Rochon, S.S. Gill, G. M. Anderson	86
14	Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design 2007 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Nathan Herrmann	8
15	Epidemiology of Social Phobia in Later Life 2007 ·American Journal of Geriatric Psychiatry ·John Cairney, (unknown), Scott Veldhuizen, Laurie Corna, David L. Streiner, Nathan Herrmann	50
16	Pharmacokinetic and Pharmacodynamic Evaluation of the Inhibition of Alprazolam by Citalopram and Fluoxetine 2003 ·Journal of Clinical Psychopharmacology ·Judith Hall, Claudio A. Naranjo, Beth Sproule, Nathan Herrmann	19
17	Pharmacotherapy for Alzheimerʼs disease and other dementias 2002 ·Current Opinion in Psychiatry ·Nathan Herrmann	3
18	Brain Reward System Activity in Major Depression and Comorbid Nicotine Dependence 2002 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), (unknown), Claudio A. Naranjo, Nathan Herrmann, Martin Zack, Usoa E. Busto	41
19	Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo* 1997 ·Clinical Pharmacology & Therapeutics ·Vural Özdemir, Claudio A. Naranjo, Nathan Herrmann, K. L. Reed, Edward M. Sellers, W. Kalow	67
20	Klinische Relevanz des Trachealbronchus 1988 ·Klinische Pädiatrie ·Nathan Herrmann, Joachim‐Hermann Scharf, B. Böwing, Kneginja Richter	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact